Pasithea Therapeutics CORP S-1 registration statements

Pasithea Therapeutics Corp. announced a public offering of up to $60 million in common stock and pre-funded warrants to fund its clinical-stage biotechnology programs, despite ongoing operating losses and Nasdaq compliance challenges.

Pasithea Therapeutics Corp. is offering up to $20.875 million in common stock, pre-funded warrants, and common warrants to fund operations and clinical trials, while facing Nasdaq delisting risk.

Pasithea Therapeutics launches a public offering of common stock and warrants, aiming to raise approximately $15.4 million to advance its pipeline of treatments for central nervous system disorders and other diseases.